Par

Par Pharmaceutical ("Par") — Company Profile

Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. are U.S. generic-drug businesses commonly referred to simply as "Par." Founded in 1978, Par traded on the NYSE (PRX) from 1987 until private-equity firm TPG Capital took it private in 2012 in a deal reported at roughly $1.9 billion. Endo International plc acquired Par in September 2015 for about $8.05 billion and merged it with its Qualitest generics unit. After Endo filed Chapter 11 in August 2022 and emerged in April 2024 as Endo, Inc. under former lender ownership, Endo merged with Mallinckrodt on July 31, 2025; on November 10, 2025 the combined generics and sterile-injectables businesses were spun off as Par Health, an independent private company headquartered in St. Louis. Par Pharmaceutical, Inc. now sits within Par Health. Historical figures: 1,152 employees (2010, as a public company); the combined Endo generics business had roughly 3,700 employees after the 2015 merger. Third-party headcount estimates for Par today conflict, so no reliable current figure is cited. Par Health reported Q3 2025 sales of $337.1 million and a portfolio of roughly 200 products.

Products / operations. Par develops, manufactures and markets generic pharmaceuticals, primarily oral solid-dose products (immediate- and extended-release tablets and capsules) plus sterile injectables (Par Sterile), active pharmaceutical ingredients, and authorized generics. It historically also marketed branded NDA injectables, including Vasostrict (vasopressin injection). It operates manufacturing and R&D sites in the U.S. and India.

Patent-litigation posture. Par is an operating company, not a non-practicing entity. In the tracked data it appears in one case, as a defendant, with zero plaintiff-side cases — consistent with a manufacturer being sued rather than asserting patents. Separately, as an ANDA filer Par was itself a frequent defendant in Hatch-Waxman patent suits, but those are not captured in the tracked case list.

Notable case. The single tracked matter is In re Xyrem (Sodium Oxybate) Antitrust Litigation (N.D. Cal., MDL No. 2966), in which Par is a defendant alongside Jazz Pharmaceuticals and generic manufacturers Hikma, Lupin and Amneal. The claims center on alleged reverse-payment patent settlements in which Par allegedly received payments and a volume-limited license in exchange for delayed generic sodium oxybate entry.